Search Bar & Filters
Found 857 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating elderly female patients aged 65 years and older with Luminal A type breast cancer that has spread to lymph nodes after surgery. This observational study aims to assess whether a 21-gene assay can predict survival outcomes and the benefits of chemotherapy in these patients. The study focuses on clinical and pathological data including imaging, treatment plans, and medication strategies to better understand disease progression and treatment impact. The study collects paraffin tissue samples from both the primary breast cancer and metastatic lymph nodes for a 21-gene assay, which calculates a recurrence risk index. Patients will be followed every 12 months after surgery to monitor for disease recurrence. After recurrence, survival is followed every three months until death. This approach allows researchers to observe real-world treatment effects and outcomes without administering experimental treatments. Participants will have their clinical information and treatment details recorded, including whether chemotherapy, radiotherapy, endocrine therapy, or targeted therapy were used after surgery. Follow-up includes regular assessments and survival tracking until the patient reaches age 80 or passes away. Data collected will help evaluate the predictive value of the 21-gene assay and guide treatment decisions for elderly breast cancer patients with lymph node involvement.
Actively Recruiting
Researchers are evaluating BLU-5937, an oral drug, in adults with refractory chronic cough, including unexplained chronic cough, in a randomized, double-blind, placebo-controlled Phase 3 study. The main goal is to assess how BLU-5937 affects 24-hour cough frequency over 24 weeks. This study also monitors safety by tracking adverse events and changes in various health parameters during the treatment period. Participants are randomly assigned to one of three groups BLU-5937 25 mg twice daily, BLU-5937 50 mg twice daily, or a matching placebo taken twice daily. The treatment lasts for 24 weeks, and participants receive their assigned oral medication regularly throughout this time. The study uses a parallel-arm design and includes an extension in China. During the study, participants undergo assessments including cough frequency measurement, vital signs, blood tests for hormones and chemistry, hematology, and ECGs at baseline and Week 24. Researchers also evaluate cough severity and quality of life using questionnaires. Safety is closely monitored by recording adverse events, treatment discontinuations, and laboratory changes. The total participation duration is 24 weeks, with follow-up assessments at specified intervals.
Actively Recruiting
Researchers are assessing the effectiveness and safety of SHR-1139 Injection for treating adult patients with ulcerative pyoderma gangrenosum, a condition involving painful skin ulcers. This is a Phase 2 clinical trial sponsored by Shandong First Medical University designed to evaluate this treatment in adults aged 18 years and older who have measurable ulcers requiring systemic therapy. Participants will receive SHR-1139 Injection as the study treatment. The main treatment period includes assessment of the ulcer closure at Week 16, focusing on complete healing of the target ulcer. The trial also monitors partial ulcer closure and safety outcomes up to Week 48, tracking any adverse events during this time. Throughout the study, participants will undergo evaluations of their ulcers at scheduled visits, including measuring the size and healing status of the target pyoderma gangrenosum ulcer. Safety assessments will be conducted regularly to monitor for any side effects. The total study duration extends to June 2028, with a primary outcome measured at Week 16 and follow-up assessments continuing up to Week 48.
Actively Recruiting
Researchers are evaluating the safety, tolerability, dosimetry, and preliminary effectiveness of 225AcAc-FAPI-XT injection in patients with advanced solid tumors that express fibroblast activation protein FAP. This early-phase clinical study focuses on patients whose cancer has progressed despite standard treatments or who lack effective standard options. The trial aims to better understand how this targeted therapy behaves in the body and its potential impact on tumor control. Participants will receive doses of 225AcAc-FAPI-XT also called XT117 given every 6 weeks. This is a single-arm study, meaning all participants receive the same investigational drug without a comparison group. The treatment targets FAP-positive tumors and involves monitoring for any side effects and measuring tumor response over time. The study treatment is administered under careful medical supervision to assess tolerance and possible benefits. Throughout the study, participants will undergo regular evaluations including scans, laboratory tests, and clinical assessments to monitor safety and tumor response. Researchers will track side effects and dose-limiting toxicities for up to two years following treatment. They will also measure outcomes such as overall response rate, duration of response, disease control rate, and progression-free survival. This comprehensive monitoring helps understand the treatments profile and guides future development. Total participation duration varies based on individual response and study timelines.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of B001 injection in patients who have neuromyelitis optica spectrum disorder NMOSD and test positive for aquaporin-4 antibodies. This condition involves recurrent attacks affecting the nervous system. The study is a multicenter, randomized, double-blind, placebo-controlled trial conducted in phases II and III to understand how well B001 works and how safe it is for these patients. Participants will receive intravenous doses of either B001 or a placebo on Day 1 and Day 15 during the randomized controlled period. The study includes two groups one receiving B001 injections and the other receiving placebo injections matching B001s schedule. The trial will extend over several years, monitoring patients closely for disease relapse and treatment side effects. During the study, participants will be regularly assessed for the time to their first NMOSD attack, changes in disability status, vision acuity, and opticospinal function. Researchers will also observe the annual relapse rate and document any adverse events. The trial includes safety monitoring for about three years to ensure comprehensive data collection on treatment impact and participant health.
Actively Recruiting
Researchers are evaluating the efficacy and safety of B007 in adults with generalized myasthenia gravis, a condition characterized by muscle weakness. This randomized, double-blind, placebo-controlled trial is sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd and aims to better understand how B007 may impact the daily activities affected by this condition. Participants will receive either B007 or a matching placebo through subcutaneous injections on days 1 and 15. The study includes different dose levels of B007 and compares outcomes over approximately 16 weeks for the primary measure, with additional assessments extending to about 24 weeks and safety monitoring for up to one year. Throughout the trial, participants will be monitored for changes in their myasthenia gravis symptoms using specific scales such as MG-ADL, QMG, MGQoL15r, and MGC. Researchers will also track any treatment-emergent adverse events. Participants are expected to maintain stable doses of their standard care treatments during the study, and the trial will last until the end of 2026, including follow-up periods for comprehensive safety and efficacy assessments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of a drug called B007 in adults with pemphigus, a condition characterized by blistering of the skin and mucous membranes. This Phase IIIII clinical trial is designed to understand how well B007 works to achieve remission with minimal treatment and to monitor its safety in this patient population. Participants will receive B007 through subcutaneous injections administered on days 1 and 15. The study measures include the proportion of patients achieving complete remission, partial remission, changes in the Pemphigus Disease Area Index PDAI, frequency of disease relapses, duration of response, and incidence of treatment-emergent adverse events. The treatment period and follow-up assessments extend up to approximately one year. During the trial, participants will be closely monitored through scheduled visits to assess disease activity and treatment response. Outcomes such as remission rates and relapse frequency will be tracked, along with safety evaluations for any adverse effects. The total participation duration includes about one year of observation after treatment initiation to fully capture treatment effects and safety data.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called B007 compared to cyclosporine in treating adults with primary membranous nephropathy, a kidney condition. This study is a multicenter, randomized, controlled, open-label trial conducted in phases II and III to better understand treatment options for this disease. Participants will be randomly assigned to receive either B007 or cyclosporin capsules. B007 is given by subcutaneous injection on days 1 and 15, while cyclosporin capsules are taken orally at a dose of 3.5 mg per kg of body weight per day. The study will observe participants over about two years to assess remission rates and monitor safety. During the trial, participants will undergo laboratory tests and assessments to track overall, complete, and partial remission rates. Researchers will also monitor any treatment-emergent adverse events or serious side effects. Participants must meet specific kidney function criteria and will be followed closely throughout the study period until its completion in late 2026.
Actively Recruiting
Researchers are studying calderasib alone and in combination with cetuximab to treat advanced solid tumors in people with the KRAS G12C mutation. The study aims to find out how many patients respond to these treatments and to evaluate their safety and tolerability. This phase 2 trial is tumor-agnostic, meaning it includes various solid tumors except colorectal cancer that have progressed despite standard treatment. Participants receive calderasib by mouth, either alone or with cetuximab given by intravenous infusion every two weeks. There is no set maximum number of treatment cycles, and participants continue until they meet criteria to stop treatment. The study is randomized and open-label, comparing the two treatment approaches in parallel groups. During the study, participants will be monitored for tumor response, adverse events, and reasons for discontinuing treatment over about 76 months. Researchers will assess progression-free survival, duration of response, and overall survival. Safety evaluations and regular clinical visits will support ongoing monitoring throughout the trial.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
1-10 of 857
1